Global Search

Hide Filters

Showing 708 results

Media Release / May 29, 2013

Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
Media Release / Apr 27, 2013

Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts

- Discounts and rebates by pharmaceutical companies are a customary, appropriate and legal practice as recognized by the Government- Physician speaker programs are also an accepted practice designed…
Media Release / Apr 26, 2013

Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
Media Release / Mar 23, 2013

FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US

- TOBI Podhaler is portable and requires no nebulizer, refrigeration or power source to deliver the medicine- TOBI Podhaler is indicated for certain cystic fibrosis (CF) patients with Pa and shortens…
Media Release / Mar 22, 2013

FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
Media Release / Mar 21, 2013

New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies

-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1-- Gilenya is the first oral…
Media Release / Mar 21, 2013

New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
Media Release / Feb 24, 2013

Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy

- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU)- CIU can be a serious, debilitating form of hives…
Media Release / Feb 24, 2013

Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Media Release / Feb 15, 2013

Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients

- Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation- Approval based on…

‹ Previous page
1
…
55
56
57
58
59
60
61
…
71
› Next page

Related News & Media